Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen [Financial Post (Toronto, Ontario, Canada)]
IQVIA Holdings, Inc. (IQV)
Last iqvia holdings, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
ir.iqvia.com
Company Research
Source: Financial Post
SAN GWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU. As a bioequivalent version of Victoza ® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA. Article content The successful development of Liraglutide highlights Adalvo's capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments. Adalvo's commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo's position as a trusted leader in the pharmaceutical industry. Click Here To View Adalvo's Diabetes Portfolio At Adalvo, there are no half-measures – they are always on target. Their mission is to be faster and stronger tha
Show less
Read more
Impact Snapshot
Event Time:
IQV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IQV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IQV alerts
High impacting IQVIA Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
IQV
News
- IQVIA Holdings Inc. (NYSE: IQV) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Prime/MRx's new Pharmacy Match technology-driven solution expands specialty pharmacy access and choice [Yahoo! Finance]Yahoo! Finance
- Gareth Williams appointed CEO of Bionical Health [Yahoo! Finance]Yahoo! Finance
- EUROAPI and Priothera enter into CDMO collaboration to advance oncology project [Yahoo! Finance]Yahoo! Finance
- Clinical Trials Market Forecast: USD 174.3 Billion by 2033, Driven by 6.8% CAGR | Dimension Market Research [Yahoo! Finance]Yahoo! Finance
IQV
Earnings
- 5/2/24 - Beat
IQV
Sec Filings
- 5/17/24 - Form 3
- 5/10/24 - Form 8-K
- 5/9/24 - Form 4
- IQV's page on the SEC website